Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy.
Saved in:
| Title: | Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy. |
|---|---|
| Authors: | Donington J; General Thoracic Surgery, University of Chicago, Chicago, Ill. Electronic address: jdonington@surgery.bsd.uchicago.edu., Hu X; Merck & Co, Inc, Rahway, NJ., Zhang S; Analysis Group, Inc, Boston, Mass., Song Y; Analysis Group, Inc, Boston, Mass., Arunachalam A; Merck & Co, Inc, Rahway, NJ., Chirovsky D; Merck & Co, Inc, Rahway, NJ., Gao C; Analysis Group, Inc, Boston, Mass., Lerner A; Analysis Group, Inc, Boston, Mass., Jiang A; Analysis Group, Inc, Boston, Mass., Signorovitch J; Analysis Group, Inc, Boston, Mass., Samkari A; Merck & Co, Inc, Rahway, NJ. |
| Source: | The Journal of thoracic and cardiovascular surgery [J Thorac Cardiovasc Surg] 2024 Oct; Vol. 168 (4), pp. 1261-1269.e1. Date of Electronic Publication: 2023 Dec 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 0376343 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-685X (Electronic) Linking ISSN: 00225223 NLM ISO Abbreviation: J Thorac Cardiovasc Surg Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1097-685X |
|---|---|
| DOI: | 10.1016/j.jtcvs.2023.12.006 |
